Sunshine Biopharma, Inc.  

(Public, OTCMKTS:SBFM)   Watch this stock  
Find more results for OTC:SBFM
0.0173
May 28 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.01 - 0.18
Open     -
Vol / Avg. 0.00/368,127.00
Mkt cap 2.47M
P/E     -
Div/yield     -
EPS -0.03
Shares 117.50M
Beta 24.48
Inst. own     -

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -808.38% -2214.83%
Return on average equity - -
Employees 3 -
CDP Score - -

Address

2015 Peel St, 5Th Fl
MONTREAL, QC H3A 1T8
Canada
+1-514-7649698 (Phone)
+1-514-7649699 (Fax)

Website links

Description

Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead drug candidate, Adva-27a is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. The Company has licensed Carbon-Difluoride Platform Technology from Advanomics. The Company’s drug candidate, Adva-27a, is a small molecule that has proven effective against different types of multidrug resistant cancer cell lines including breast cancer (MCF-7/MDR), small-cell lung cancer (H69AR), uterine carcinoma (MES-SA/Dx5) and pancreatic cancer (Panc-1). The early stage preclinical studies for Adva-27a were completed in 2011.

Officers and directors

Steve N. Slilaty Chairman of the Board, President, Chief Executive Officer
Age: 62
Camille Sebaaly Chief Financial Officer, Secretary, Director
Age: 54
Abderrazzak Merzouki Chief Operating Officer, Director
Age: 51